Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- CMHC
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Hundreds of practitioners gathered in Boston in October 2022 for the annual conference from Cardiometabolic Health Congress (CMHC). In the past 17 years, this medical conference has grown to be the biggest and most-anticipated event in evidence-based education for the diagnosis, treatment, and management of cardiometabolic diseases and risk factors. The On-Demand program includes all recordings from the general sessions of the live meeting; CME Symposia are posted as separate activities within the CMHC Educational Platform.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors for continued ASCVD residual risk.
- CMHC
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk. The evolving evidence with GLP-1 RA in this setting has led to important studies and guideline changes, all with significant implications for patient management.
- CMHC
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that clinicians face in reducing the burden of anemia in patients with CKD.
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with this condition. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), including medications, implantable cardioverter defibrillators, ventricular assist devices, or heart transplant. Additionally, despite a higher HF symptom burden, women are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps.
- ACCME (All Other)
- ACCME (MD/DO Only)
- ACPE Pharmacy
- ANCC
$0.00
How rare is a rare disease?While the number of people affected by an individual rare disease may be small, the total number of people with a rare diseases—an estimated 25 to 30 million in the United States—is enormous!What is Pompe disease?It is a glycogen storage disease type II and considered to be a rare inherited autosomal recessive disorder caused by mutations in the gene that encodes for acid alpha-glucosidase (GAA).
- CMHC
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
During this recorded symposium from the 2022 American Heart Association (AHA), you will get a chance to:Learn more about the importance of chronic kidney disease and type 2 diabetes as major drivers of cardiovascular morbidity and mortalityBe up-to-date about the data with novel nonsteroidal MRAs in cardiorenal risk reduction, and how this new approach fits in with existing treatment options
- CMHC
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
This clinical brief was developed from a presentation at the 17th annual CMHC Annual Congress held from October 19-22, 2022 in Boston, MA. The session, “Why Should We Use CGM in Patients With Type 2 Diabetes? Assessing the Evidence and Practical Pearls for Integration,” was presented by Irl B Hirsch, MD from the University of Washington, Seattle, WA, supported by an educational grant from Dexcom, Inc.
- LivDerm
- TME
- AMA PRA Category 1 Credit™
- ANCC
- Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Additionally, studies have uncovered risk factors for AA that clinicians need to be aware of when treating either pediatric or adult patients.
- CMHC
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
$0.00
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps. In this activity, experts overview the efficacy and safety of these new approaches, how they fit in with the current treatment options for LDL-C lowering, and application to